Paolo Pucci

Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway.

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million.